Amyris Inc (AMRS) to Post Q3 2019 Earnings of $0.07 Per Share, B. Riley Forecasts
Amyris Inc (NASDAQ:AMRS) – Analysts at B. Riley boosted their Q3 2019 earnings per share estimates for shares of Amyris in a research report issued to clients and investors on Tuesday. B. Riley analyst C. Driscoll now forecasts that the biotechnology company will post earnings per share of $0.07 for the quarter, up from their previous estimate of $0.06. B. Riley has a “Buy” rating and a $10.00 price target on the stock. B. Riley also issued estimates for Amyris’ Q4 2019 earnings at $0.21 EPS.
Other research analysts have also issued research reports about the company. HC Wainwright restated a “buy” rating and set a $15.00 price objective on shares of Amyris in a research report on Thursday, January 18th. Cowen restated a “hold” rating and set a $4.00 price objective on shares of Amyris in a research report on Wednesday, November 29th. Zacks Investment Research upgraded Amyris from a “sell” rating to a “hold” rating in a research report on Tuesday, March 13th. Finally, ValuEngine upgraded Amyris from a “strong sell” rating to a “sell” rating in a research report on Friday, February 23rd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the stock. Amyris presently has a consensus rating of “Hold” and a consensus target price of $8.19.
Amyris (NASDAQ:AMRS) last released its quarterly earnings data on Thursday, March 15th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.07 by ($0.24). The company had revenue of $80.59 million during the quarter, compared to analyst estimates of $68.14 million. During the same period in the prior year, the company earned ($0.09) EPS. Amyris’s revenue for the quarter was up 262.4% on a year-over-year basis.
In other Amyris news, insider John Melo sold 10,776 shares of the business’s stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $4.68, for a total transaction of $50,431.68. Following the completion of the transaction, the insider now owns 83,172 shares in the company, valued at approximately $389,244.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 11.30% of the company’s stock.
A number of hedge funds have recently made changes to their positions in AMRS. Creative Planning acquired a new position in Amyris during the 4th quarter worth $188,000. KBC Group NV raised its stake in shares of Amyris by 228.4% in the 3rd quarter. KBC Group NV now owns 60,154 shares of the biotechnology company’s stock worth $192,000 after buying an additional 41,834 shares in the last quarter. Compagnie Lombard Odier SCmA raised its stake in shares of Amyris by 60.0% in the 4th quarter. Compagnie Lombard Odier SCmA now owns 104,000 shares of the biotechnology company’s stock worth $390,000 after buying an additional 39,000 shares in the last quarter. Hudson Bay Capital Management LP bought a new stake in shares of Amyris in the 4th quarter worth $451,000. Finally, Tanaka Capital Management Inc. raised its stake in shares of Amyris by 72.0% in the 3rd quarter. Tanaka Capital Management Inc. now owns 528,549 shares of the biotechnology company’s stock worth $1,691,000 after buying an additional 221,295 shares in the last quarter. Institutional investors own 22.27% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Amyris Inc (AMRS) to Post Q3 2019 Earnings of $0.07 Per Share, B. Riley Forecasts” was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The original version of this piece can be accessed at https://www.watchlistnews.com/amyris-inc-amrs-to-post-q3-2019-earnings-of-0-07-per-share-b-riley-forecasts/1961106.html.
Amyris Company Profile
Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.
Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.